Zafgen, Inc. (NASDAQ:ZFGN) has earned an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $6.33.

A number of brokerages have recently issued reports on ZFGN. Zacks Investment Research lowered shares of Zafgen from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. ValuEngine upgraded shares of Zafgen from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th. Finally, Roth Capital initiated coverage on shares of Zafgen in a research report on Thursday, April 20th. They set a “buy” rating and a $9.00 target price on the stock.

Zafgen (NASDAQ ZFGN) traded down 3.53% on Tuesday, hitting $3.55. 127,330 shares of the company were exchanged. The stock has a 50 day moving average price of $3.80 and a 200 day moving average price of $4.11. The firm’s market cap is $97.17 million. Zafgen has a one year low of $2.89 and a one year high of $6.87.

Zafgen (NASDAQ:ZFGN) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, equities research analysts forecast that Zafgen will post ($2.34) EPS for the current fiscal year.

In other Zafgen news, insider Dennis D. Kim purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The stock was acquired at an average cost of $4.40 per share, with a total value of $44,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 21.20% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Parametric Portfolio Associates LLC increased its stake in shares of Zafgen by 55.8% in the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 10,327 shares during the last quarter. Nine Chapters Capital Management LLC purchased a new stake in shares of Zafgen during the first quarter valued at approximately $170,000. Wells Fargo & Company MN increased its stake in shares of Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 40,400 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Zafgen by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 5,794 shares during the last quarter. Finally, Federated Investors Inc. PA increased its stake in shares of Zafgen by 27.0% in the fourth quarter. Federated Investors Inc. PA now owns 129,661 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 27,533 shares during the last quarter. 52.00% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/18/zafgen-inc-nasdaqzfgn-receives-consensus-rating-of-hold-from-analysts.html.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.